IntegraGen recently posted their recent colorectal research on Oncotarget. The study linked miR-31-3p expressions to the emergence of metastatic colorectal cancer. Metastatic colorectal cancer, mCRC is a huge menace in the world. Today, there are over 1.3 million new cases of mCRC reported in the US alone. What’s more, the severely debilitating condition reportedly claims the lives of over 650,000 individuals worldwide every year.
IntegraGen is a Paris based research firm trading under the initials, ALINT. The pharmaceutical giant specializes in developing robust and efficient oncology treatment and diagnostic tools. The center shocked the entire oncology world with a medical journal titled, ‘Association between miR-31-3p expression & Cetuximab efficacy in metastatic colorectal cancer patients’. The research demonstrated a strong correlation between the manifestation of cancerous tumors and the expression of the miR-31-3-3p. Additionally, the clinical trials proved the incredible efficiency of the firm’s anti-EGFR cancer treatment.
The historic cancer clinical trial was carried out by a team from the prestigious University College London Cancer Institute led by the oncology expert, Professor John Bridgewater. The professor’s final submissions included similar research findings by the New EPOC cancer research study. Speaking after the publication went live, Prof. Bridgewater termed the anti-EGFR therapy as an absolute game-changer towards treating the virulent colorectal cancer tumors in millions of patients. The professor also commended the partners who’d made the study possible.One of the lead research partners in the oncology findings, Dr. Yann Gaston-Mathe hoped to see more cancer patients recovering thanks to the precision expression testing approach, moving forward. Dr. Yann Gaston-Mathe is a Molecular Diagnostics Director at IntegraGen.
Future Projects by IntegraGen
IntegraGen has in the past worked on CE-IVD markers that are now commercially used all over Europe. The easy to use miRpredX 31-3p marker kits developed by IntegraGen have helped speed up the diagnosis of this cancer variety and consequently, save the lives of millions of cancer patients. IntegraGen is in the process of releasing yet another vital laboratory kit that will be used to measure the expressions of miR-31-3p. The latter project involves the CEBRA laboratories and is scheduled to launch in the coming year.The miRpredX 31-3p test is the world’s premier positive colorectal cancer test. The test helps physicians to determine the best course of treatment for patients who turn up positive. In cases when the cancer is not as advanced, the oncologists resort to using the anti-EGFR therapy as the first-line of defense and in critical cases, the experts go with the chemotherapy option. At times, the physicians see it fit to combine the two therapeutic approaches to save the life of the RAS wild-type colorectal cancer patients.
Oncotarget is on the top 100 list of the most respected American medical journals, according to www.scimagojr.com. The peer-reviewed platform operates on the open access license forum. The platform has encouraged international collaboration among cancer researchers from different corners of the globe. Due to unprecedented demand, the journal publishes weekly periodicals that focus on not just cancer treatments, but a variety of other medical genres as well. Oncotarget is a popular peer-to-peer reviewed medical publication journal founded in late 2010 by the revered cancer researchers, Andrei V. Gudkov and Mikhail Blagosklonny.